NCT03457467
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Radiation Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT03457467